Boston Scientific (BSX) Receives a Hold from Needham

In a report released today, Michael Matson from Needham maintained a Hold rating on Boston Scientific (BSXResearch Report). The company’s shares closed last Tuesday at $45.39.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 16.9% and a 68.9% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $49.56, which is an 11.1% upside from current levels. In a report issued on July 22, Deutsche Bank also maintained a Hold rating on the stock with a $45.00 price target.

See today’s analyst top recommended stocks >>

Boston Scientific’s market cap is currently $62.48B and has a P/E ratio of 314.10. The company has a Price to Book ratio of -54.85.

Based on the recent corporate insider activity of 126 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Boston Scientific Corporation engages in the manufacturing of medical devices and products that are used in various interventional medical specialties worldwide. The company provides implantable devices including heart monitors, technologies for treating coronary artery disease and other cardiovascular disorders, and devices for diagnosing and treating gastrointestinal and pulmonary problems.